Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.
about
Hypolipidemic and antihypertensive drugs for prevention of cardiovascular complications in patients with rheumatoid arthritisEndothelial Dysfunction and Inflammation: Immunity in Rheumatoid ArthritisRole of T cells in type 2 diabetic nephropathyAngiotensin II in inflammation, immunity and rheumatoid arthritisA Dormant Microbial Component in the Development of PreeclampsiaHematopoietic stem cell transplantation and acute kidney injury in children: A comprehensive review.Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic DisordersRegulation of oxidative stress and cardioprotection in diabetes mellitus.Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine.A systematic review and meta-analysis of genetic association studies for the role of inflammation and the immune system in diabetic nephropathy.How I treat late effects in adults after allogeneic stem cell transplantation.Inflammatory cytokines in diabetic nephropathy.AT1 receptor antagonism does not influence early radiation-induced changes in microglial activation or neurogenesis in the normal rat brain.Losartan increases bone mass and accelerates chondrocyte hypertrophy in developing skeleton.Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity.Effects of angiotensin II blockade on inflammation-induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockersAn angiotensin II receptor antagonist reduces inflammatory parameters in two models of colitis.Chronic kidney disease after liver, cardiac, lung, heart-lung, and hematopoietic stem cell transplant.Effect of Acupuncture on Body Weight Reduction and Inflammatory Mediators in Egyptian Obese PatientsWhite blood cell count in women: relation to inflammatory biomarkers, haematological profiles, visceral adiposity, and other cardiovascular risk factorsRisk-based classification of hypertension and the role of combination therapy.Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker.Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.The association of cardioprotective medications with pneumonia-related outcomes.Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study.Prevention of Stroke in Rheumatoid Arthritis.The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy.Acute adriamycin-induced cardiotoxicity is exacerbated by angiotension IIGW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats.High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin.Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synoviumThe restoration of kidney mitochondria function by inhibition of angiotensin-II production in rats with acute adriamycin-induced nephrotoxicity.Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project.Inflammation alters angiotensin converting enzymes (ACE and ACE-2) balance in rat heart.Prevention of stroke in rheumatoid arthritis.Instillation of particulate matter 2.5 induced acute lung injury and attenuated the injury recovery in ACE2 knockout mice.
P2860
Q24242787-FC9ACFE9-D8E2-4EF6-B4DF-79D8C92ED7D2Q26749294-39EBDC97-3BC2-4BC7-A6EE-860F80F46F7CQ26849691-122EB2DF-DBCE-42E8-82BF-85CE338C200DQ26991828-B7C09C6D-8158-436E-8D3B-1451E397498EQ28069689-95C3CE8D-2BB4-4282-A9A8-4720882448E8Q30234519-D7FCCB79-3067-4913-BEFE-EBDD3EE3E437Q33166521-65033F58-827D-4B4A-B9A9-A65DE8902EA6Q33572259-F2003C79-727D-44C4-B462-A47B5037CFF2Q33715408-AF5A5390-E711-4520-8257-63FB597FB123Q33783045-21CBB7F6-2168-4015-9077-987E7483BCD9Q34707208-EAE4D469-8949-4EA4-8076-A7E0064B79DAQ35133177-98607E26-D189-437E-BEFB-C3248BF2126FQ35173719-52FF42E8-18BC-4061-8B41-F26C4CD5DCA3Q35588952-632BC124-6C94-46FD-8294-6C4F2663926CQ35624602-D3B55C79-B35D-4356-8F71-7E1C4CE68183Q36381540-262AAB1D-AF6B-479F-8451-26DA7C14AF3AQ36484871-874DA367-3E21-4D46-A842-28E22945D49AQ36585425-5AC64E30-5BEA-431E-ACD7-B8776002F057Q36929124-F08E62B5-60FB-4783-9F82-A7E632F4FE21Q36985349-7F157EDE-3925-4BC3-AE21-C38E7DB46B7CQ37050143-5A5BB875-25F3-4883-A400-442E930FB3E2Q37050156-FAA4548D-8037-41E4-A841-E7B7C2178918Q37058791-4D60875D-1EF4-4AF0-A365-4E863819F990Q37525118-97358913-720A-4B5D-BC16-29E9F6064E9BQ37579475-0518826E-67AF-40FC-90BC-5FA1603CB393Q38612651-CD8FA562-5D8E-4607-AC6A-C8DC07A149CCQ41126974-4DF322BE-B794-4434-AF1F-9F9C31B7C9DBQ41376836-C0F05B80-4B67-460B-BE90-E2EDE7A4CF0CQ41586886-7D9002BF-4248-477F-8551-B4993F1BEA8FQ41807679-65BE0CB2-F1E5-4E74-B29F-1C0CAAFCB10CQ42378890-6DFA5D5A-35ED-4611-89F2-990BA250116FQ46935336-114FCC76-7D72-4967-B015-940B9DDA590EQ47859328-AC0A9BFB-59BF-4C84-A355-6331F107B600Q52604902-045A734B-ECBC-4C0C-99A2-FB21120B5944Q53502883-23660E69-288C-4229-B73A-1ED250F61E65Q55018195-B42B51F7-8F19-44F6-B89A-4C42C4C76B86
P2860
Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.
@ast
Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.
@en
type
label
Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.
@ast
Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.
@en
prefLabel
Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.
@ast
Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.
@en
P2860
P1433
P1476
Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.
@en
P2093
Fakhreddin Jamali
Nigel J Dagenais
P2860
P304
P356
10.1592/PHCO.2005.25.9.1213
P407
P577
2005-09-01T00:00:00Z